Drug intelligence / Profile preview

INDV-6200

Development stage: Phase 1
Lead developer: Indivior
Modality: Small Molecules

Overview

INDV-6200 is an investigational small molecule drug being developed for the treatment of opioid dependency. It is designed to provide sustained plasma concentrations of buprenorphine, a medication commonly used in opioid use disorder therapy. The mechanism of action involves partial agonism at the mu-opioid receptor (OPRM) and antagonism at the kappa-opioid receptor (OPRK), which together help reduce opioid cravings and withdrawal symptoms while minimizing abuse potential. The developer is Indivior[1].

Targets

MOR (Mu opioid receptor)KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on INDV-6200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INDV-6200.

Explore the full profile